Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q4 FY2025 Earnings Presentation
22 slides from Balaxi Pharmaceuticals's earnings presentation, Jun 7, 2025
Slide 1: Cover letter to National Stock Exchange
Balaxi Pharmaceuticals Limited Date:07.06.2025 To, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai — 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30
Slide 2: Balaxi Pharmaceuticals Limited Investor Presentation
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
' Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actua
Slide 4: Corporate Snapshot, Financial Highlights, Strategic Roadmap
04 Corporate Snapshot 14 Financial Highlights 20 Strategic Roadmap Balaxi
Slide 5: Balaxi company overview
Branded IPR-based pharma company Frontier markets leadership in Latin America and Africa Vast portfolio across diverse therapeutic areas Asset light structure for expansion in semi-regulated markets Balaxi
Slide 6: Supply Chain, Distribution, Transformation
Expansion initiated: Ecuador, Chile (Latin America) 915 product registrations in Seven countries 300+ registrations submitted or in the pipeline Establishing the Company’s first Supply Chain pharmaceutical formulation facility in Hyderabad Successful process being replicated in other Distribution fr
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology = Focus on countries with high-potential economic growth framework = |dentify non-English speaking countries with similar characteristics = Low competitive intensity and potential to establish top-2 position = On-ground feedback mechanism allows deep
Slide 8: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” Marketing and Market Research ’ Product Product Manufacturing ’ Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from ‘Asset Light’ to Asset Rig
Slide 9: Investment in Manufacturing Facilities
' Investment in Manufacturing Facilities Lo . L] . . L] L] . ° . L] Setting up its first pharmaceutical formulation manufacturing unit ° General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain
Slide 10: Global Footprint
' Global Footprint Portugal Existing Market Dominican ‘ € Republic @ Targeted Expansion Guatemala )Honduras El salvador agua @ rroduct Sourcing Regions Ecuador Balaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of S 6 billion Tfi aiaxi 9
Slide 11: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 12: Corporate Structure
Corporate Structure laxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) 1 1 v Balaxi Balaxi Balaxi Balaxi . Healthcare Healthcare Healthcare Healthcare Healthcare Balaxi Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Healthcare Nicaragua SRL (WOS) S.A (WOS) (WOS) (WOs) (WOS)
Slide 13: Board of Directors
Ashish Maheshwari /Minoshi Maheshwari /Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi experience, manages First Water
Slide 14: Dynamic Leadership Team
Dynamic Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associat
Slide 15: Financial Highlights
FINANCIAL HIGHLIGHTS Balaxi
Slide 16: Management commentary on FY25
“FY25 has been a pivotal year in Balaxi Pharmaceutical’s growth journey. The Company delivered a strong recovery, marked by solid execution, and a strategic pivot in our go-to-market approach. By targeting newer sales channels — including institutional (hospital) and tender business — and deepening
Slide 17: Financial Performance FY25 (INR crore)
Particulars (INR crore) . Revenue Gross Margin EBITDA EBITDA Margin % Profit After Tax PAT Margin % Earnings Per Share (INR) *NOTE: During the 1t quarter of the FY 24, the Angolan currency Kwanza underwent an unprecedented sharp depreciation, falling from 511.50 AOA/USD to 832.5 AOA/USD. Since the c
Slide 18: Pharma Product Mix FY25
Pharma Product Mix— FY25 Geographies Products m Africa* = Branded u LATAM** = Generics Therapeutic Areas P Dosage Forms M m Tablets m Antibiotics = Injectables = Analgesic = Liquids = Anti-malaria = Capsules = Others m Others Balax’ *Africa: Angola and Central African Republic *LATAM — Guatemala, Do
Slide 19: Quarterly Financial Performance (Consolidated)
“Quarterly Financial Performance (Consolidated) Particulars (InR crore) Q4 FY24 Revenue 59.83 30.95 Gross Margin % 51.7% EBITDA 11.68 EBITDA Margin % 19.5% Profit After Tax 10.93 PAT Margin % 18.3% Earning Per Share (INR) 2.08 *Exceptional Item pertaining to Q4 FY24 : 1.08 cr. Balaxi
Slide 20: Pharma Product Mix Q4 FY25
Pharma Product Mix— Q4 FY25 Geographies Products m Africa* LU u Branded u LATM** = Generics Dosage Forms Therapeutic Areas m Tablets m Antibiotics = Injectables = Analgesic o AREE = Liquids = Anti-malaria = Capsules A = Others m Others Balax’ *Africa: Angola and Central African Republic *LATM - Guat
Slide 21: Core Strategy: Enter, Expand & Excel
' Core Strategy: Enter, Expand & Excel s Balaxi in 2020: Business Consolidation .. = Presence across Angola, Guatemala and Dominican Republic = Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-24: Expansion into New Geographies = Aim
Slide 22: Our Offerings and Contact
Our Offerings one Balaxi Pharmaceuticals Limited Medical Device Anti-Emetic Plot No. 409, H.No. 8-2-293, 3rd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Anti-Mala nchodilator Telangana Anemia CIN: L25191TG1942PLC121598 @ Sunny Purohit | Antacid @ +91-40-2355-5300 * Tuberculosis M sunny@b
Balaxi Pharmaceuticals — Q4 FY2025 Earnings Presentation on 6ix